ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Terbinafine

Also written as “MOB015B”, “terbinafine” and “Terbinafine Hydrochloride”.

Its studies are mostly in Onychomycosis · Erythema · Tinea Pedis · Mycoses · Fasting, led by 13 companies.

Drug pageTerbinafine: every studyMany companies study it; this page follows only the 33 they lead. All 46 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Aug 4, 201633 company-led studies, 2 open or runningNext primary completion: Jan 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Moberg Pharma ABits history only71 open or runningphase 3since Aug 4, 2016Mar 15, 2013none ahead
Novartisits history only70 open or runningphase 3since Jun 30, 2005Nov 2, 1999none ahead
Almirallits history only30 open or runningphase 3since Sep 8, 2015Sep 8, 2015none ahead
Celtic Pharma Development Servicesits history only20 open or runningphase 3since Mar 19, 2010Mar 18, 2010none ahead
Dr. Reddy's Laboratoriesits history only20 open or runningphase 1since Jan 26, 2011Jan 26, 2011none ahead
Hikma Pharmaceuticals20 open or runningno phasesince Jan 15, 2008Jan 15, 2008none ahead
Nitric BioTherapeuticsits history only20 open or runningphase 2since Mar 1, 2010Mar 1, 2010none ahead
Teva Pharmaceutical Industriesits history only20 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
Viatrisits history only20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
GlaxoSmithKlineits history only10 open or runningphase 1since Jan 17, 2013Jan 17, 2013none ahead

Also a collaborator on its studies: PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hikma Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2008First studies: 2 no phase studies in OnychomycosisFirst studyNCT00602342, NCT00602251

TargetBeta

SQLE →read by rule
“Squalene monooxygenase inhibitor; Squalene monooxygenase inhibitor”ChEMBL 37, by rule
“Terbinafine is a long-licensed, generic antifungal drug that inhibits squalene epoxidase (SQLE), an enzyme that may play a role in prostate cancer progression.”study text, by rule · the study

Studies

All 2 Hikma Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00602342Onychomycosis · United States–CompletedApr 200430
NCT00602251Onychomycosis · United States–CompletedApr 200430

How it is read

Names in the registry

  • “MOB015B”, 7 entries
  • “terbinafine”, 4 entries
  • “Terbinafine”, 3 entries
  • “Terbinafine Hydrochloride”, 3 entries
  • “Terbinafine HCl 250mg tablets”, 2 entries

Codes read as this program: P3058.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.